Home » Stocks » ACIU

AC Immune SA (ACIU)

Stock Price: $6.52 USD -0.21 (-3.12%)
Updated Apr 19, 2021 3:44 PM EDT - Market open
Market Cap 489.28M
Revenue (ttm) 17.54M
Net Income (ttm) -70.36M
Shares Out 72.70M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $6.52
Previous Close $6.73
Change ($) -0.21
Change (%) -3.12%
Day's Open 6.72
Day's Range 6.40 - 6.81
Day's Volume 238,947
52-Week Range 4.42 - 13.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Dr. Colowick has more than 20 years of experience in large and emerging biotech companies

2 weeks ago - GlobeNewsWire

Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics Clinically validated platform accelerates the...

2 weeks ago - GlobeNewsWire

Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases

3 weeks ago - GlobeNewsWire

Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to ($0.28), wh...

3 weeks ago - Benzinga

LAUSANNE, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today repo...

3 weeks ago - GlobeNewsWire

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Other stocks mentioned: CANF, MRNA
1 month ago - Benzinga

Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43

1 month ago - GlobeNewsWire

Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.

2 months ago - The Motley Fool

Swiss biopharma AC Immune has released positive updates this week on both its Alzheimer's and Parkinson's disease treatments. Investors are piling in to ACIU stock.

2 months ago - InvestorPlace

AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-...

2 months ago - Benzinga

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's disease

2 months ago - GlobeNewsWire

LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...

2 months ago - GlobeNewsWire

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors

2 months ago - GlobeNewsWire

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital

4 months ago - GlobeNewsWire

Prof. June is a world authority on immune tolerance and adoptive immunotherapy

4 months ago - GlobeNewsWire

Prof. Streffer is a n established authority on n euroscience and b iomarker modalities

5 months ago - GlobeNewsWire

AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate...

5 months ago - Benzinga

LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...

5 months ago - GlobeNewsWire

Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development

5 months ago - GlobeNewsWire

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.

5 months ago - Seeking Alpha

Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program

6 months ago - GlobeNewsWire

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

6 months ago - Zacks Investment Research

AC Immune S.A. (NASDAQ: ACIU) stock was absolutely crushed on Wednesday after one of the firm’s partners announced disappointing results from its midstage Alzheimer’s disease study.

6 months ago - 24/7 Wall Street

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug.

6 months ago - Benzinga

AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.

6 months ago - The Motley Fool

Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met

6 months ago - GlobeNewsWire

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseas...

7 months ago - GlobeNewsWire

Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 months ago - Zacks Investment Research

AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

First-in-class TDP-43 antibody developed using SurpraAntigen™ platform

8 months ago - GlobeNewsWire

AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results present...

8 months ago - GlobeNewsWire

Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio

8 months ago - GlobeNewsWire

Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases Presentations to highlight the Company’s broad expertise address...

8 months ago - GlobeNewsWire

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

9 months ago - Zacks Investment Research

Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.

9 months ago - The Motley Fool

AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.

9 months ago - Investors Business Daily

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company.

9 months ago - Benzinga

Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study

9 months ago - GlobeNewsWire

Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool

9 months ago - GlobeNewsWire

LAUSANNE, Switzerland, June 26, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative disease...

9 months ago - GlobeNewsWire

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Latest appointment further reinforces the depth and breadth of the Company’s clinical development competences in Down syndrome-related Alzheimer’s disease Latest appointment further reinforces the depth...

1 year ago - GlobeNewsWire

AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for January 30th

Other stocks mentioned: AGYS, AXP
1 year ago - Zacks Investment Research

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ASND, EYEN, NGM, SAGE
1 year ago - Zacks Investment Research

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative disea...

1 year ago - GlobeNewsWire

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph... [Read more...]

Industry
Biotechnology
IPO Date
Sep 23, 2016
CEO
Andrea Pfeifer
Employees
125
Stock Exchange
NASDAQ
Ticker Symbol
ACIU
Full Company Profile

Financial Performance

Financial numbers in millions CHF.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AC Immune stock is "Buy." The 12-month stock price forecast is 13.87, which is an increase of 112.73% from the latest price.

Price Target
$13.87
(112.73% upside)
Analyst Consensus: Buy